CtDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
Ozempic and Cardiovascular Risk: New Findings Demand Closer scrutiny
What Happened? A Closer Look at the SELECT trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic). The study, involving over 17,600 participants, showed a statistically notable, though relatively small, increase in these events compared to a placebo group.This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
understanding the SELECT trial: Key Details
The SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease. Participants did not have diabetes. They were randomly assigned to receive either 2.4 mg of semaglutide weekly or a placebo, in addition to their standard care. The primary outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. The median follow-up period was 3.95 years.
| Outcome | Semaglutide Group (n=8831) | Placebo Group (n=8801) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Cardiovascular Death | 3.7% | 2.6% | 1.44 (1.11-1.86) |
| Nonfatal Myocardial Infarction | 2.6% | 1.9% | 1.32 (0.98-1.78) |
| Nonfatal Stroke | 3.7% | 2.3% | 1.58 (1.13-2.21) |
| Unstable Angina Requiring hospitalization | 1.2% | 0.8% | 1.53 (0.88-2.66) |
| Composite Cardiovascular Outcome | 9.6% | 7.3% | 1.31 (1.09-1.57) |
What Does This Mean? Beyond the Numbers
The observed hazard ratio of 1.31 for the composite cardiovascular outcome indicates a 31% increased risk in the semaglutide group. While statistically significant, it’s crucial to understand this doesn’t mean that 31% of patients on Ozempic *will* experience a cardiovascular event. It represents a relative increase in risk compared to the placebo group. The absolute risk difference was 2.3%, meaning that for every 1000 patients treated with semaglutide for approximately four years, there were approximately 23 additional cardiovascular events.